Lucence | Advancing Precision Cancer Care Fight cancer with a single draw of blood Lucence makes ultrasensitive and non-invasive Liquid Biopsy Tests for cancer detection and treatment
LiquidHALLMARK® Liquid Biopsy: Personalized Cancer Care - Lucence Lucence works with biopharmaceutical companies globally across all stages of the development pipeline from target discovery to companion diagnostics We are able to customize LiquidHALLMARK to meet your needs
| Lucence Lucence exists to push the limits of molecular diagnostics with purpose and precision – bringing clarity to cancer care Saving lives is our life’s work With sensitive and non-invasive liquid biopsy tests, we provide doctors and their “cancer-fighters” life-changing information so that they can seek effective treatments
Lucence Launches LucenceINSIGHT to Detect Cancer Earlier Lucence is launching LucenceINSIGHT™, an MCED test first internationally and with a follow-up U S launch in Q3 2023 This ctDNA-based liquid biopsy test screens for 10 common cancers in one blood draw Globally, 78% of cancer deaths occur in cancers without recommended routine screening [1]
News Events - Lucence Lucence Secures MolDX Approval for LiquidHALLMARK® ctDNA and ctRNA Liquid Biopsy Test to Advance Non-Invasive Cancer Diagnostics
Agilus Diagnostics and Lucence Announce Strategic Collaboration to . . . Lucence’s proprietary technology will empower Agilus Diagnostics to expand its oncology capabilities, offering liquid biopsy-based screening for early cancer detection, recurrence monitoring, and therapy personalization
Lucence and Diagnostics Development Hub (DxD Hub) Collaborate on . . . Lucence and the Diagnostics Development Hub (DxD Hub), a national platform hosted by the Agency for Science, Technology and Research (A*STAR) are collaborating to develop and pivot the use of Lucence’s multi-cancer early detection test (LucenceINSIGHT™) on alternative sample types This collaboration represents a significant advancement in